首页> 美国卫生研究院文献>Clinical Orthopaedics and Related Research >Osteonecrosis after Allogeneic Bone Marrow Transplantation
【2h】

Osteonecrosis after Allogeneic Bone Marrow Transplantation

机译:同种异体骨髓移植后的骨坏死

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Osteonecrosis after bone marrow transplantation is usually severe. Most patients develop acute and chronic graft-versus-host disease requiring a high dose of steroids for a long period of time. Generally ineffective nonoperative treatment in the past has resulted in treatment primarily with total hip arthroplasty (THA). We asked whether THA (1) reliably improved functional status, (2) led to more complications, and (3) THA after bone marrow transplantation was as durable as THA for idiopathic ON. We retrospectively reviewed 77 patients (123 hips) with osteonecrosis. The mean age at surgery was 33 years (range, 15.7–56 years). We performed all arthroplasties with an alumina ceramic bearing coupled with an alumina head 32 mm in diameter. The minimum followup was 2 years (mean, 9.2 years; range, 2–26 years). We documented seven revisions: three for late septic loosening, four for late aseptic loosening. Considering loosening of any component as the end point, the survivorship was 74.8% (range, 58.7%–90.9%) at 10 years. In this difficult situation, we believe the results acceptable. Septic loosening affecting this specific population has to be considered a serious event.>Level of Evidence: Level IV, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.
机译:骨髓移植后的骨坏死通常很严重。大多数患者发展为急性和慢性移植物抗宿主病,需要长期服用高剂量的类固醇。过去通常无效的非手术治疗已导致主要采用全髋关节置换术(THA)进行治疗。我们询问THA(1)是否能可靠地改善功能状态,(2)导致更多的并发症,以及(3)骨髓移植后的THA是否与特发性ON的THA一样持久。我们回顾性分析了77例(123髋)骨坏死患者。手术的平均年龄为33岁(范围为15.7-56岁)。我们使用氧化铝陶瓷轴承和直径为32毫米的氧化铝头进行了所有关节置换术。最小随访时间为2年(平均9.2年;范围2至26年)。我们记录了七个修订版本:三个用于晚期败血症的松动,四个用于晚期败血症的松动。考虑到任何组成部分的松动为终点,在10年时的存活率为74.8%(范围为58.7%–90.9%)。在这种困难的情况下,我们相信结果是可以接受的。影响该特定人群的脓毒症松动必须视为严重事件。>证据级别: IV级,治疗研究。有关证据水平的完整说明,请参见《作者指南》。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号